Zhejiang Huakang Pharmaceutical Co., Ltd. (SHA:605077)
China · Delayed Price · Currency is CNY 17.08
+0.29 (1.73%)
Apr 29, 2026, 1:35 PM CST
SHA:605077 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,189 | 2,795 | 2,731 | 2,180 | 1,588 |
Other Revenue | - | 13.79 | 51.27 | 19.52 | 6.47 |
| 4,189 | 2,808 | 2,783 | 2,200 | 1,594 | |
Revenue Growth (YoY) | 49.15% | 0.92% | 26.48% | 38.02% | 20.79% |
Cost of Revenue | 3,559 | 2,198 | 2,111 | 1,696 | 1,227 |
Gross Profit | 629.45 | 610.82 | 671.82 | 503.69 | 367.13 |
Selling, General & Admin | 165.12 | 186.1 | 127.68 | 106.63 | 80.71 |
Research & Development | 144.92 | 128.41 | 124.28 | 99.71 | 84.23 |
Other Operating Expenses | -3.87 | 4.85 | 6.33 | -8.96 | 8.11 |
Operating Expenses | 306.18 | 337.97 | 258.46 | 204.27 | 178.96 |
Operating Income | 323.27 | 272.84 | 413.36 | 299.43 | 188.17 |
Interest Expense | - | -33.45 | -37.15 | -14.24 | -3.9 |
Interest & Investment Income | 16.57 | 32.12 | 28.27 | 48.53 | 57.7 |
Currency Exchange Gain (Loss) | - | 15.9 | 7.21 | 26.45 | -2.55 |
Other Non Operating Income (Expenses) | -94.48 | -1.07 | -0.86 | -4.84 | -0.44 |
EBT Excluding Unusual Items | 245.36 | 286.35 | 410.82 | 355.33 | 238.98 |
Gain (Loss) on Sale of Investments | 3.68 | -1.76 | 5.3 | -10.27 | 1.78 |
Gain (Loss) on Sale of Assets | 0.1 | -0.14 | -0.01 | 0.03 | 0.05 |
Asset Writedown | -23.25 | -0.49 | -4.27 | -2.31 | -1.39 |
Other Unusual Items | - | 2.61 | 10.56 | - | 14.64 |
Pretax Income | 225.89 | 286.57 | 422.4 | 342.78 | 254.07 |
Income Tax Expense | 23.18 | 17.78 | 50.02 | 23.5 | 17.36 |
Earnings From Continuing Operations | 202.7 | 268.79 | 372.38 | 319.28 | 236.71 |
Minority Interest in Earnings | -2.41 | -0.31 | -0.93 | - | - |
Net Income | 200.3 | 268.48 | 371.45 | 319.28 | 236.71 |
Net Income to Common | 200.3 | 268.48 | 371.45 | 319.28 | 236.71 |
Net Income Growth | -25.40% | -27.72% | 16.34% | 34.88% | -22.94% |
Shares Outstanding (Basic) | 303 | 298 | 297 | 296 | 288 |
Shares Outstanding (Diluted) | 303 | 378 | 297 | 296 | 288 |
Shares Change (YoY) | -19.74% | 27.25% | 0.23% | 3.09% | 28.98% |
EPS (Basic) | 0.66 | 0.90 | 1.25 | 1.08 | 0.82 |
EPS (Diluted) | 0.66 | 0.71 | 1.25 | 1.08 | 0.82 |
EPS Growth | -7.04% | -43.20% | 16.07% | 30.84% | -40.25% |
Free Cash Flow | -58.98 | -1,283 | -71.23 | -267.77 | -96.61 |
Free Cash Flow Per Share | -0.19 | -3.39 | -0.24 | -0.90 | -0.34 |
Dividend Per Share | - | 0.500 | 0.538 | 0.462 | 0.330 |
Dividend Growth | - | -7.15% | 16.68% | 40.02% | -16.02% |
Gross Margin | 15.03% | 21.75% | 24.14% | 22.89% | 23.03% |
Operating Margin | 7.72% | 9.71% | 14.85% | 13.61% | 11.80% |
Profit Margin | 4.78% | 9.56% | 13.35% | 14.51% | 14.85% |
Free Cash Flow Margin | -1.41% | -45.69% | -2.56% | -12.17% | -6.06% |
EBITDA | 615.54 | 472.14 | 586.2 | 404.88 | 272.57 |
EBITDA Margin | 14.70% | 16.81% | 21.07% | 18.40% | 17.10% |
D&A For EBITDA | 292.27 | 199.3 | 172.84 | 105.45 | 84.4 |
EBIT | 323.27 | 272.84 | 413.36 | 299.43 | 188.17 |
EBIT Margin | 7.72% | 9.71% | 14.85% | 13.61% | 11.80% |
Effective Tax Rate | 10.26% | 6.20% | 11.84% | 6.86% | 6.83% |
Revenue as Reported | - | 2,808 | 2,783 | 2,200 | 1,594 |
Advertising Expenses | - | 7.95 | 7.89 | 9.97 | 6.92 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.